The deactivation of PP2A in cancer is typically caused by mutations, post-translational modifications, or the increased expression of endogenous PP2A inhibitors, such as Suvar/Enhancer of zeste/Trithorax (SET) or cancerous inhibitor of PP2A (CIP2A) [8]. This evidence concerns the gene PTPA and cancer.